Review Article

Beneficial Effects of Citrus Flavonoids on Cardiovascular and Metabolic Health

Ayman M. Mahmoud,1 Rene J. Hernández Bautista,2 Mansur A. Sandhu,3 and Omnia E. Hussein1

1Physiology Division, Department of Zoology, Faculty of Science, Beni-Suef University, Egypt
2Metropolitan Autonomous University, Laboratory of Bioenergetics and Cellular Aging, Department of Health Sciences, Division of Health and Biological Sciences, Mexico
3Biomedical Sciences Department, Faculty of Veterinary & Animal Sciences, PMAS Arid Agriculture University, Pakistan

Correspondence should be addressed to Ayman M. Mahmoud; ayman.mahmoud@science.bsu.edu.eg

Received 20 October 2018; Revised 6 January 2019; Accepted 30 January 2019; Published 10 March 2019

Academic Editor: Luigi Iuliano

Copyright © 2019 Ayman M. Mahmoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The prevalence of cardiovascular disease (CVD) is increasing over time. CVD is a comorbidity in diabetes and contributes to premature death. Citrus flavonoids possess several biological activities and have emerged as efficient therapeutics for the treatment of CVD. Citrus flavonoids scavenge free radicals, improve glucose tolerance and insulin sensitivity, modulate lipid metabolism and adipocyte differentiation, suppress inflammation and apoptosis, and improve endothelial dysfunction. The intake of citrus flavonoids has been associated with improved cardiovascular outcomes. Although citrus flavonoids exerted multiple beneficial effects, their mechanisms of action are not completely established. In this review, we summarized recent findings and advances in understanding the mechanisms underlying the protective effects of citrus flavonoids against oxidative stress, inflammation, diabetes, dyslipidemia, endothelial dysfunction, and atherosclerosis. Further studies and clinical trials to assess the efficacy and to explore the underlying mechanism(s) of action of citrus flavonoids are recommended.

1. Introduction

Diabetes mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia and defective insulin secretion, insulin action or both [1, 2]. DM is associated with significant morbidity and mortality due to its related complications particularly on the cardiovascular system [3, 4]. Recent reports estimated that there are 415 million diabetic patients worldwide, and the number is projected to increase and may reach 642 million by 2040 [5]. The chronic and prolonged hyperglycemia in DM is associated with increased risk of developing cardiovascular disease (CVD) [6]. Hyperglycemia induces excessive generation of reactive oxygen species (ROS) in the diabetic heart, resulting in oxidative stress [7]. Hyperglycemia-mediated oxidative stress represents the main pathophysiological mechanism behind the development of diabetic cardiomyopathy (DCM) and many other cardiovascular alterations [8]. DCM is characterized by diastolic dysfunction, cardiac remodeling, hypertrophy, and altered cardiac energy metabolism [9, 10]. Within the diabetic heart, increased levels of ROS induce cardiac injury by direct damage of the cellular macromolecules, including lipids, proteins, and DNA [11, 12]. In addition to oxidative stress, hyperglycemia can induce mitochondrial dysfunction, inflammation, increased advanced glycation end products (AGEs), and activation of protein kinase C (PKC) and polyol pathways [10]. Moreover, dyslipidemia has emerged as a major factor in the pathogenesis of DCM [13].

Atherosclerosis is a chronic inflammatory process of large- and medium-sized arteries, characterized by the abnormal deposition of fibrous tissue, cholesterol, and lipid plaques in the inner most layer of the arteries [14]. This disease leads to narrowing of arteries and disturbs the basic structure of vessels which lead to partial and/or complete blockage of arteries. Atherosclerosis of coronary artery results in irregular blood flow which leads to ischemic heart...
failure and myocardial infarction [15]. Different risk factors are responsible for the pathogenesis of atherosclerosis, and those include hyperlipidemia, hypertension, endothelial dysfunction (ED), smoking, and diabetes. In addition, different inflammatory and immunological features play a pivotal role in the development of the disease process, as macrophages containing oxidizing particles discharge different inflammatory substances including cytokines and different growth factors such as intercellular adhesion molecule (ICAM-1); monocyte chemoattractant protein-1 (MCP-1); macrophage colony-stimulating factor; interleukin (IL-) 1, 3, 6, 8, and 18; and tumor necrosis factor (TNF-α) [16, 17]. Cell proliferation and ROS production are accelerated by proinflammatory cytokines, which ultimately stimulate the metalloproteinases leading to expression of tissue factor, which results in leukocyte activation, ED, and initiation of atherosclerosis [18–20].

Flavonoids are plant-based natural products that are very abundant and have multiple therapeutic benefits and biological activities. This diverse group of compounds exerts anti-inflammatory, anti-oxidative, anti-carcinogenic, anti-hyperammonemia, nephroprotective, and hepatoprotective activities as we reported previously [21–29]. The basic structure of flavonoids involves 15-carbon atoms and 2 phenolic rings carrying one or more hydroxyl group (OH). According to their structure, flavonoids could be divided into 6 classes: flavanones, flavones, flavanols, isoflavones, flavonols, and anthocyanids [30]. There are thousands of food flavonoid compounds existing in glycosyl form or bound to glycosides [31, 32]. Dietary flavonoids in nature exist as glycosides, such as, glucoside, galactoside, arabinoside, rhamnoside, and rutinoside [33, 34]. All dietary flavonoids except flavanols are found in glycosylated forms [35], and deglycosylation is a critical step in the absorption and metabolism of flavonoid glycosides [36]. The flavonoid glycosides are water-soluble, whereas aglycones are more hydrophobic and can be easily absorbed [32, 37, 38]. Within the small intestine, only aglycones and some glucosides can be absorbed; however, flavonoids linked to a rhamnose moiety must be hydrolyzed by rhamnosidases of the microflora in the large intestine [39, 40]. The flavonoid glycosides are then absorbed, bound to albumin, and transported to the liver via the portal vein [41–43]. The intrahepatic metabolism of flavonoids is influenced by different factors [31], and flavonoids and their derivatives may undergo hydroxylation, methylation, and reduction [42]. Citrus fruits are notably rich in flavonoid compounds and represent an important source of dietary flavonoids, including hesperidin, hesperetin, naringin, naringenin, diosmin, quercetin, rutin, nobiletin, tangeretin, and others (Figure 1). These flavonoids are present in many citrus fruits, such as, bergamots, grapefruit, lemons, limes, mandarins, oranges, and pomelos [44]. The health-related effects of citrus flavonoids have been reported in several studies. Among their biological activities, citrus flavonoids possess radical scavenging, antioxidant, and anti-inflammatory properties. Given the role of oxidative stress in the pathogenesis of CVD, including DCM, and atherosclerosis, we aim in this review to focus on the mechanisms of action of citrus flavonoids in oxidative stress, diabetes, DCM, lipid metabolism, adipose tissue inflammation, ED, platelet function, and atherosclerosis.

2. Biological Activities of Citrus Flavonoids

2.1. Citrus Flavonoids and Oxidative Stress. Flavonoids possess multiple health benefits, including antioxidant and free radical scavenging, anti-inflammatory, and cytoprotective effects [45–48]. Given the role of oxidative stress and inflammation in the pathogenesis of obesity, diabetes, and CVD [4, 49–53], the antioxidant potential of flavonoids may play a key role in their beneficial therapeutic effects. The chemical structure of flavonoids indicates that they act as radical scavengers, oxygen quenchers, and hydrogen-donating antioxidants. Therefore, flavonoids can boost endogenous antioxidants and prevent the formation of ROS and their subsequent cell damage [54].

Flavonoids can prevent cell injury through the direct scavenging of free radicals and hence prevent their deleterious effects. Flavonoids are oxidized by free radicals, resulting in a more stable flavonoid radical and less reactive free radicals. Some flavonoids can directly scavenge superoxide, whereas others can scavenge peroxynitrite (ONOO−). The presence of OH groups permits high flavonoid reactivity against ROS and reactive nitrogen species (RNS). Flavonoids can stabilize OH−, peroxyl (ROO−), and ONOO− radicals. The antioxidant efficacy of a given flavonoid increases in function with the number of OHs in the structure of the molecule [48, 55]. For example, the 5-OH substitution and a 5,7-m-dihydroxy arrangement in the A-ring is an important feature of naringenin, making it a potent antioxidant with stabilized structure after donating H to the R2 [55].

Oxidative stress is a frequent pathological contributor to most liver diseases. The concerted work of oxidative stress and inflammation may increase production of the extracellular matrix (ECM) followed by fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and finally liver failure [55]. Naringenin has been reported to suppress lipid peroxidation and protein carbonylation, enhance antioxidant defenses, scavenge ROS, modulate signaling pathways related to fatty acid metabolism, lower lipid accumulation in the liver, and thereby prevent fatty liver [55, 56].

By scavenging radicals, flavonoids can inhibit low-density lipoprotein (LDL) oxidation and therefore may have preventive action against atherosclerosis [57]. Several studies from Mahmoud’s lab have documented the effects of flavonoids on cellular redox status and inflammation in different diseases, including HCC [29], diabetes [58], diabetic retinopathy [58], and drug-induced hepatotoxicity [28]. Other studies have demonstrated the beneficial role of citrus flavonoids in nonalcoholic fatty liver disease (NALFD), the most common liver disease caused by high fat consumption, vitamin and energy deficiency, and inflammatory processes [55, 56].

Citrus flavonoids have been shown to improve lipid metabolism, and their effects are thought to be mediated via their antioxidant capacity [59, 60]. Rutin is a powerful radical scavenger, and its scavenging ability may be due to its inhibitory activity on the enzyme xanthine oxidase (XO). The antioxidant effect of naringenin is primarily attributed to reducing ROS and enhancing the antioxidant defenses, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) in chronic diseases [48].
Figure 1: Chemical structure of the common citrus flavonoids.
Naringenin has shown a protective effect against nephrotoxicity induced by vancomycin, a drug used in severe infections. Vancomycin-induced rats treated with different doses of naringenin showed a significant amelioration in oxidative stress and apoptosis markers. Naringenin ameliorated serum creatinine and blood urea nitrogen levels and kidney nitric oxide (NO) and caspase-3/8 activities. However, the protective effect of naringenin was associated with the dose. At moderate doses, naringenin exerted a protective role, but at higher doses the protective effect was decreased [61]. In vitro treatment of the RAW264.7 cells with naringenin suppressed the inflammatory mediators and suppressed AGEs [62]. Rats treated with naringenin and quercetin for 14 days showed improved neurocognitive functions, enhanced antioxidant defenses, and suppressed lipid peroxidation in the brain [63]. In a rat model of diabetic retinopathy, naringenin attenuated oxidative stress and apoptosis and boosted the antioxidants. In addition, naringenin ameliorated the levels of brain-derived neurotrophic factor, tropomyosin-related kinase B, synaptophysin, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and caspase-3 in the retina of diabetic rats [64]. The beneficial therapeutic effects of naringenin are mediated, at least in part, via its antioxidant and radical scavenging properties [64]. However, the exact mechanisms underlying the antioxidant efficacy of naringenin are not fully understood. In the study of Wang et al., isolated neurons cultured in vitro under conditions of hypoxia and reoxygenation showed increased production of ROS. Treatment with naringenin resulted in a significant decrease in ROS production and improved mitochondrial function evidenced by increased levels of high-energy phosphates, increased mitochondrial membrane potential, and decreased apoptosis [65].

Hesperidin and its aglycone hesperetin, two flavonoids found primarily in oranges and lemons, have shown multiple beneficial effects, such as, anticarcinogenic, antihypertensive, antiviral, antioxidant, antidiabetic, hepatoprotective, and anti-inflammatory [28, 29, 58, 66]. Several studies have been conducted to explore the pharmacological activities, molecular targets, and mechanisms of action of hesperidin. Hesperidin can decrease capillary permeability, leakiness, and fragility [67, 68]. The antioxidant efficacy of hesperidin was not limited only to its radical scavenging activity, but it also enhanced the cellular antioxidant defenses via the extracellular signal–regulated kinase (ERK)/nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling pathway [67]. Nrf2 is a redox-sensitive transcription factor that activates the transcription of antioxidant and cytoprotective enzymes [4]. Recently, studies have focused on the protective effects of hesperidin and hesperetin against ROS and oxidative stress. In this context, we have previously demonstrated the antioxidant activity of hesperidin against hyperglycemia-induced oxidative stress in high-fat diet (HFD)/streptozotocin- (STZ-) induced diabetic rats. Hesperidin significantly decreased lipid peroxidation and increased the levels of reduced glutathione (GSH), vitamin C, and vitamin E and enhanced the activity of antioxidant enzymes SOD, CAT, and GPx in type 2 diabetic rats [58]. We also demonstrated the antioxidant efficacy of hesperidin in a rat model of cyclophosphamide-induced liver injury. Our results showed suppressed lipid peroxidation, NO, inducible nitric oxide synthase (iNOS), and nuclear factor-kappaB (NF-κB) and boosted enzymatic and nonenzymatic antioxidant defenses in the liver of hesperidin-treated rats. We reported that the upregulation of peroxisome proliferator-activated receptor (PPARγ) mediated, at least in part, the antioxidant and anti-inflammatory potential of hesperidin [28]. More recently, we investigated the antioxidant efficacy of hesperidin in a hepatocarcinogenesis rat model. Our results showed the ability of hesperidin to prevent the increased production of ROS, NO, and lipid peroxides and to enhance both enzymatic and nonenzymatic defenses in the liver of rats subjected to chemically induced hepatocarcinogenesis. In addition, we reported that the mechanism of action of hesperidin included upregulation of PPARγ and Nrf2/antioxidant response element (ARE)/antioxidant signaling pathways [29].

In addition to its ability to upregulate PPARγ and Nrf2 signaling pathways, there is evidence that attenuation of endoplasmic reticulum (ER) stress is one of the effects of hesperidin. In this context, treatment of the ovarian cancer cell line A2780 with hesperidin decreased the viability in a dose- and time-dependent manner. This effect was mediated via induction of apoptosis as shown by the increased levels of cleaved caspase-3. Hesperidin upregulated the protein expression levels of anti-CCAT/enhancer-binding protein (C/EBP-) homologous protein/growth arrest and DNA damage-inducible gene 153 (GADD153), glucose-regulated protein (GRP) 78, and cytochrome c. These findings point to the role of ER stress signaling in mediating the impact of hesperidin on A2780 cells [69].

A recent study conducted by Wunpathe et al. [70] demonstrated the role of hesperidin in suppressing excessive ROS production mediated via renin-angiotensin system-mediated NADPH oxidase (NOX2) overexpression in hypertensive rats. In a rat model of two-kidney-one-clipped (2K-1C) hypertension, hesperidin reduced blood pressure in a dose-dependent manner and decreased plasma angiotensin (AT) II levels and aortic AT I receptor protein expression. In addition, hesperidin attenuated oxidative stress via suppressing NADPH oxidase in hypertensive rats [70].

The free radical-scavenging and immunomodulatory properties of hesperidin have been postulated to mediate its protective effect against X-irradiation-induced oxidative damage. Exposure to X-irradiation induced cardiovascular complications, including myocardial degeneration, vascular leakage, myocyte necrosis, development of plaque, inflammation, and fibrosis. Rats receiving hesperidin showed decreased cardiac lipid peroxidation, inflammation, fibrosis, and other complications and enhanced the activity of antioxidant enzymes [71].

Hesperetin, the aglycone of hesperidin, possesses a well-documented antioxidant efficacy. In a rat model of lead acetate-induced oxidative stress, hesperetin showed a significant antioxidant efficacy evidenced by the decreased lipid peroxidation and increased levels of GSH and activity of SOD, CAT, and GPx [68]. Hesperetin exerted a protective effect against oxidative stress in the testis of diabetic rats. Oral
administration of hesperetin for 45 days suppressed ROS production, protein carbonylation, and oxidative DNA damage. In addition, hesperetin ameliorated GSH, SOD, CAT, and GPx in the testicular tissue of diabetic rats. In conjunction with attenuating oxidative stress, hesperetin prevented inflammation and apoptosis as evidenced by the low levels of proinflammatory cytokines and caspase-3 activity in diabetic rats [72]. Furthermore, hesperetin exerted a cardioprotective effect in doxorubicin-induced rats. Administration of hesperetin for 5 weeks reduced cardiac lipid peroxidation, increased GHS levels, and prevented oxidative DNA damage and apoptosis as shown by comet and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assays, respectively [73].

The antioxidant capacity of other citrus flavonoids, including nobiletin, rutin, and tangeretin, has also been tested. Nobiletin, tangeretin, 5-demethylnobiletin (5-DN), and 5-demethyltangeretin (5-DT) are polymethoxyflavones found in aged citrus peels. These flavonoids have been reported to ameliorate cell tolerance, ROS production, and lipid peroxidation in Saccharomyces cerevisiae [74]. In mutant Saccharomyces cerevisiae deficient in glutathione synthase, CAT, or SOD, nobiletin, tangeretin, 5-DN, and 5-DT activated CAT under stress induced by carbon tetra-chloride (CCL4), hydrogen peroxide (H2O2), and cadmium sulfate [74]. Nobiletin has also protected human retinal pigment epithelial cells against damage induced by H2O2, as shown by increased cell viability and suppressed ROS and activity of caspases [75]. The protective effect of nobiletin was associated with increased phosphorylation of protein kinase B (PKB/Akt), pointing to the role of phosphoinositide 3-kinase (PI3K)/Akt signaling in mediating the effects of nobiletin [75]. Through its ability to prevent excessive production of ROS, nobiletin inhibited cadmium-induced neuronal apoptosis and modulated c-Jun N-terminal kinase (JNK)/ERK1/2 and Akt/mTOR signaling, expression of the kinases MKK and ASK1, and phosphorylation of S6K1, Akt, and 4E-BP1 [76]. Previous research from our lab has demonstrated the antioxidant efficacy of rutin. In a rat model of hyperammonemia, rutin prevented lipid peroxidation and improved the antioxidant defenses of GSH, SOD, and GPx [26]. In type 2 diabetic rats, rutin inhibited hyperglycemia-induced oxidative stress and increased the hepatic antioxidant defenses [22]. Furthermore, rutin protected against oxidative stress in a rat model of hepatocarcinogenesis [77].

2.2. Citrus Flavonoids and Lipid Metabolism. Lipids are essential for maintaining various physiologic and homeostatic processes within the body. Dysregulation of the lipid and lipoprotein metabolism is one of the major risk factors leading to CVD, obesity, diabetes, and inflammation [45, 46, 59]. Several studies have demonstrated the beneficial role of citrus flavonoids in modulating lipid metabolism and attenuating several diseases, including obesity and atherosclerosis. However, the mechanisms underlying the therapeutic effects of citrus flavonoids are not fully understood. While human studies have emphasized the dose, bioavailability, efficacy, and safety, citrus flavonoids suppressed atherogenesis through ameliorating metabolic parameters and their direct impact on the vessel wall in rodents [59]. Citrus flavonoids can control calorie intake versus expenditure and regulate lipid metabolism, and their use as safe and natural alternatives to treat obesity is currently under investigation.

Although hesperidin and naringin reduced serum total and LDL-cholesterol in rodent models of diabetes [21], human studies showed no effect on serum cholesterol levels in moderately hypercholesterolemic men and women [78]. In vitro treatment of the hepatoma cell line HepG2 with naringenin and hesperetin for 4 hr reduced apoB100 accumulation in the media [79]. Naringenin and hesperetin suppressed microsomal triglyceride transfer protein and acyl-CoA:cholesterol acyltransferase in HepG2 cells [80]. Other in vitro studies using HepG2 cells showed inhibited apoB secretion and cholesterol synthesis following treatment with tangeretin and nobiletin, whereas sinesetin, hesperetin, and naringenin exerted weak effects [81]. The different effects of citrus flavonoids on apoB secretion and cholesterol synthesis could be attributed to differences in their molecular structure [81, 82].

The sterol regulatory element-binding proteins (SRE BPs), transcriptional regulators of lipid synthetic genes, have been assumed to be implicated in mediating the effects of citrus flavonoids on lipid metabolism. In this context, a mutation of the SRE in the LDL receptor (LDLR) gene upstream region attenuated the effects of hesperetin and nobiletin in HepG2 cells [81]. Hesperidin stimulated LDLR gene expression in HepG2 cells via increasing the phosphorylation of PI3K and ERK1/2 and SREBP-2 mRNA abundance [83]. These effects can reduce plasma LDL levels and hence show the cardioprotective potential of hesperidin [83]. HepG2 cells with luciferase reporter-gene constructs incorporating the promoters of SREBP-1a, -1c, and -2, and LDLR, treated with 200 μM naringenin in lipoprotein-deficient medium (LPDM), showed increased SREBP-1a promoter activity after 4 hr. After treatment for 24 hr, the gene expression levels of SREBP-1a, -1c, and -2 and LDLR promoter-constructs were increased [84]. In addition, naringenin suppressed SREBP-1c acetyl-CoA carboxylase and fatty acid synthase mRNA expression in HepG2 cells [84].

Other mechanisms mediating the effects of citrus flavonoids on lipid metabolism have been postulated. Hesperetin might be implicated in ghrelin secretion from stomach. Ghrelin may be related with the pathophysiological mechanisms of a variety of human disorders, including lipodystrophies [85]. Using Caenorhabditis elegans as a model, Peng et al. showed that hesperidin decreased fat accumulation; downregulated the expression of steeroyl-CoA desaturase, fat-6, and fat-7; and suppressed other genes involved in lipid metabolism, including pod-2, mdt-15, acs-2, and kat-1 [86]. In addition, mutations of fat-6 and fat-7 reversed fat accumulation inhibited by hesperidin [86]. Millar et al. have recently discussed the effects of flavonoids on reverse cholesterol transport (RCT), high-density lipoprotein (HDL) metabolism, and HLD function [46]. Given the role of inflammation in the induction of dysfunction of HDL particles, flavonoids can improve HDL function via attenuating oxidative stress and inflammation [46].
Previous work from our laboratory showed improved serum HDL levels in type 2 diabetic rats treated with hesperidin and naringin [21]. Long-term consumption of flavonoid-rich foods has been associated with improved circulating levels of total cholesterol, triglycerides, and LDL-cholesterol [87]. Preclinical in vitro and in vivo studies reported the influence of flavonoids on RCT and HDL function by regulating the activity and expression of hepatic paraoxonase 1 and cholesterol efflux from macrophages [46]. However, clinical studies targeting the effect of citrus flavonoids on HDL function are lacking [46].

Studies on the effects of flavonoids such as apigenin (apigenin 7-O-glucoside) on adipogenesis have suggested similar effects for citrus flavonoids. Apigenin, a flavonoid present in several plant leaves and seeds, significantly inhibited lipid accumulation and reduced the gene expression levels of C/EBP-α, PPAR-γ, SREBP-1c, fatty acid synthase (FAS), and proinflammatory cytokines in 3T3-L1 cells [88]. Similar effects have been exerted by citrus flavonoids. In 3T3-L1 adipocytes, nobiletin, an O-methylated flavone isolated from citrus peels, upregulated the beige-specific genes Cd137, Cidea, Tbx1, and Tmem26 and the protein expression of PKA and p-AMPK (5′-adenosine monophosphate-activated protein kinase) [89]. In addition, nobiletin upregulated the key transcription factors responsible for remodeling of white adipocytes, induced mitochondrial biogenesis, modulated several proteins related to lipid metabolism (CPT1, ACOX1, FAS, SREBP, SIRT1, and p-PLIN), and suppressed JNK and c-Jun [89]. Therefore, the citrus flavonoid nobiletin can induce browning and ameliorate stress in white adipocytes [89]. The effects of pure total flavonoids on lipid metabolism have also been tested. HFD-fed rats treated with the pure total flavonoids from Citrus aurantium for 4 weeks showed improved body weight, ameliorated serum cholesterol and triglycerides, enhanced antioxidant defenses, and upregulated gene and protein expression levels of PPAR-α and LPL [90].

2.3. Citrus Flavonoids and Adipose Tissue Inflammation. Adipose tissue stores lipid in the form of triglycerides and secretes a variety of mediators that regulate a number of cellular processes. It secretes a variety of adipocytokines and is therefore currently considered an endocrine organ. In addition to the rapid expansion of adipose tissue [59], chronic low-grade inflammation associated with insulin resistance and other metabolic disturbances are characteristic features of obesity [59, 91–93].

Flavonoids possess a potent anti-inflammatory potential, and several studies demonstrated their ability to attenuate inflammation associated with different diseases [25–29, 58, 59, 94]. Citrus fruits represent a source of flavonoids, and their consumption has been associated with reduced cardiovascular events that can also be associated with obesity, suggesting their cardioprotective potential [92, 95]. Multiple in vitro and in vivo studies provided strong evidence supporting the protective effect of flavonoids against vascular disturbances associated with obesity [92, 93]. The anti-inflammatory potential of flavonoids may be attributed to their ability to bind cyclooxygenases (COXs). COXs catalyze the conversion of arachidonic acid into prostaglandins and thromboxanes. COX-2 is an inducible form that is expressed upon stimulation and produces prostaglandins for the induction of the inflammation and pain [57]. In silico studies have demonstrated the ability of flavonoids, flavones, and flavonones to bind COX-2, and this can help in developing potent inhibitors for the treatment of inflammation [57].

In lipopolysaccharide- (LPS-) stimulated RAW 264.7 cells, naringenin suppressed TNF-α and IL-6 release in a dose-dependent manner. Naringenin treatment downregulated gene expression levels of COX-2, TNF-α, IL-6, iNOS, and NOX-2 in LPS-stimulated macrophages [96]. These findings demonstrate the potent anti-inflammatory potential of naringenin. Other flavonoids, including apigenin, genistein, and kaempferol, have exerted COX-2 inhibitory effects via suppressing NF-κB activation. Orotoril A (5,7-dihydroxyflavone 6 methyl ether), a flavone isolated from Scutellaria radix, showed a similar effect where it suppressed iNOS and COX-2 through inhibition of NF-κB activation [97]. In addition, pure flavonoids and flavonoid-enriched extracts can reduce the expression of cytokines and COX-2 [98].

Previous work from our lab has shown the anti-inflammatory effect of hesperidin and naringin in HFD/STZ-induced diabetic rats. Both flavonoid compounds decreased the levels of circulating proinflammatory cytokines and downregulated the expression of IL-6 in adipose tissue [27, 58]. A recent study by Ke et al. [99] showed that naringenin reduced adipose tissue mass, adipocyte size, and body weight and ameliorated adipose tissue inflammation in HFD-fed obese ovariectomized mice [99]. The same group demonstrated that naringenin decreases adipose tissue mass and attenuates metabolic disturbances in ovariectomized mice. Naringenin-fed ovariectomized mice exhibited over 50% reduction in subcutaneous and visceral adiposity, decreased hepatic lipid accumulation, and significantly downregulated MCP-1 and IL-6 mRNA in perigonadal adipose tissue [100].

Hesperetin and naringenin showed anti-inflammatory potential in mouse adipocytes. Both flavonoid compounds inhibited TNF-α-stimulated free fatty acid (FFA) release and blocked the activation of NF-κB and ERK pathways in mouse adipocytes. Through ERK signaling inhibition, hesperetin and naringenin prevented the suppressing effect of TNF-α on the antipolyolipidic genes perilipin and PDE3B. In addition, the suppressive effect of hesperetin and naringenin on NF-κB resulted in IL-6 downregulation and subsequently reduced FFA secretion from mouse adipocytes [101]. During the differentiation of adipocytes, naringenin has been reported to inhibit toll-like receptor- (TLR-) 2 expression, an effect mediated via upregulation of PPARγ [102]. In this context, hesperidin has been reported to activate PPARγ signaling in hepatocytes [28, 29]. In differentiated adipocytes, naringenin inhibited TNF-α-induced activation of TLR2 and NF-κB [102]. In vivo studies showed that naringenin suppresses the infiltration of macrophages into the adipose tissue of mice fed a HFD for 14 days [103]. In addition, naringenin inhibited the c-Jun NH2-terminal kinase pathway and subsequently downregulated MCP-1 expression in the adipose tissue of HFD-fed mice [103].
In vitro cultured/cocultured adipocytes and macrophages showed suppressed MCP-1 expression following treatment with naringenin [103].

The beneficial role of naringenin and nobiletin in obesity and adipose tissue has been supported by using knockout mice. In the study of Burke et al. [92], Ldlr−/− mice fed a high-fat-high cholesterol diet and treated with naringenin and nobiletin exhibited a significant improvement in metabolism and decreased obesity.

3. Therapeutic Potential of Citrus Flavonoids in Diabetes and DCM

3.1. Citrus Flavonoids and DM. DM occurs as a consequence of irregular catabolism and anabolism of carbohydrates, lipids, and proteins because of insulin resistance or hypoinsulinism [104]. On the basis of etiology and clinical signs, DM is classified into three types, type 1 DM, type 2 DM, and gestational DM. Type 1 DM is an insulin-dependent or juvenile diabetes and also termed as diabetes insipidus. Clinically, it is characterized by an autoimmune disorder against β-cells present in the islets of Langerhans of the endocrine pancreas. Around 5-10% of all diabetic patients are suffering from type 1 DM [105]. The initial incidence of type 1 DM usually occurs at the age of 4 years, or when the individual reaches in early adolescence and puberty, i.e., below the age of 20 years. In the early stages, individuals suffering from type 1 DM show mild fasting hyperglycemia, and this may progress to severe hyperglycemia and/or ketoadosis, indicating impaired function of pancreatic β-cells. Upon diagnosis, 80-90% of patients suffering from type 1 DM will have elevated levels of auto-antibodies to insulin, including glutamic acid decarboxylase (GAD65), and tyrosine phosphates IA-2 and IA-2β [106]. Type 1 DM signs are extreme urination and thirst, episodic hunger, gradual weight, and vision loss [106].

Type 2 DM is a non-insulin-dependent or adult onset of diabetes. Currently, type 2 DM is the most prevalent type of diabetes in the world and accounts for 90-95% patients [107]. Type 2 DM is considered as heterogeneous disease, because multiple factors are mixed up in its progression, including obesity, lack of physical activity, hypertension, and dyslipidemia. In this type of diabetes, the body produces sufficient amount of insulin but due to cellular resistance, it remains ineffective. Upon diagnosis of type 2 DM, almost every patient has some degree of impaired insulin secretion [108].

Gestational diabetes mellitus (GDM) is present or diagnosed during the 2nd/3rd trimester of pregnancy. Although GDM is a tentative disorder, it may increase the chances of getting type 2 DM later in life. Women with elevated level of blood glucose during pregnancy are diagnosed with GDM. Normally, GDM starts during the 24th week of pregnancy. Oral glucose tolerance test (OGTT) is recommended in high-risk women for the diagnosis of GDM. Women diagnosed with GDM are in jeopardy of elevated blood pressure, fetal macrosomia, and difficulty in vaginal birth [109]. Although GDM disappears after pregnancy, it may reappear in future pregnancies and may lead to type 2 DM in later stages of life. Additionally, the infants of GDM mothers are at threat of type 2 DM development during adolescence or in early adulthood [109].

Antioxidants are compounds which have the ability to delay or inhibit the oxidation of different molecules in the body. Although a low amount of ROS is beneficial in cell signaling, increased ROS is the major cause of cell death [110]. Different studies have proposed that phytochemicals either from fruit or vegetable sources can protect cells from ROS-induced damage [111].

Rutin, a natural citrus flavonoid found in fruits and vegetables, has effective efficacy in lowering hyperglycemia and also acts as an antioxidant [112]. A previous trial has shown that rutin supplementation significantly decreases glucose levels in diabetic patients [113]. Two studies have documented protective effects of rutin in diabetic rodent models [22, 114]. Another study showed that chronic hyperglycemia and dyslipidemia are a potential source of ROS in diabetes and may be a source of oxidative stress through different mechanisms, including autoxidation of glucose, lipid peroxidation, the polyol pathway, and glycosylation [115]. In vivo, rutin suppressed oxidative stress and partly reduced hyperglycemia and dyslipidemia in healthy rats but produced significant reduction in blood glucose and increased the activity of carbohydrate metabolic enzymes in diabetic rats [112]. Rutin increased insulin levels by stimulating the intact β cells to produce insulin and may protect functional β cells from further damage [112]. Previous research from our laboratory showed that the antidiabetic effect of rutin is mediated via ameliorating hyperglycemia, hyperlipidemia, insulin secretion, oxidative stress, inflammation, gluconeogenesis, glycogenolysis, peripheral glucose uptake, and intestinal glucose absorption in type 2 diabetic rats [22].

Nobiletin is another citrus flavonoid possessing adipocyte differentiation inhibitory activity [116] and can reduce the development of obesity which is directly correlated with type 2 diabetes. Nobiletin can act as an antidiabetic agent [117] and interferes with the differentiation of the 3T3-L1 preadipocyte cell line by inhibiting the extracellular signaling-regulated protein kinase signal pathway [116]. A study conducted by Lee et al. [117] showed that nobiletin has significant effects, including enhancement of Akt phosphorylation and glucose transporter− (GLUT−) 1 expression in complete cellular lysates and GLUT-4 in plasma membranes of white adipose tissue and muscles. In the same study, the effects of nobiletin were evaluated on the metabolism of glucose and insulin sensitivity in obese and diabetic ob/ob mice, where results have shown that 5-week treatment with nobiletin improved the circulating glucose level, homeostasis model assessment (HOMA) index, and results of OGTT.

Diosmin (DS) is a common component of many citrus fruits and has an ability to stimulate the activity of β cells [118, 119]. A previous study has shown that oral treatment with DS for 45 days in diabetic rats significantly reduced plasma glucose level and enhanced the activity of hexokinase and glucose-6-phosphate dehydrogenase (G6PD) [118].

Hesperidin and naringin are very common citrus flavonoids and not only attenuate the diabetic condition but also
can revoke neuropathic pain by controlling hyperglycemia and hyperlipidemia which upregulate the generation of free radicals and release of proinflammatory cytokines [120]. We have conducted different in vivo and in vitro studies to explore the mechanisms underlying the antidiabetic effects of hesperidin and naringin. In one study, both hesperidin and naringin attenuated hyperglycemia-induced oxidative stress and inflammation in HFD/STZ-induced type 2 diabetic rats. Both compounds reduced hyperglycemia, glycosylated hemoglobin levels, lipid peroxidation, TNF-α, and IL-6 and enhanced enzymatic and nonenzymatic antioxidant defenses [58]. In another study, both hesperidin and naringin prevented hematological alterations and modulated the expression of IL-6 and adiponectin in the adipose tissue of type 2 diabetic rats [27]. We have also shown that hesperidin and naringin improved serum insulin, hepatic and muscle glycogen, and gene and protein expression of GLUT-4. In addition, both compounds ameliorated hepatic glucose output, peripheral glucose uptake, intestinal glucose absorption, and glucose-stimulated insulin secretion from isolated islets of Langerhans [121].

Eriodictyol is a lemon citrus flavonoid and has significant ability to reduce oxidative stress in diabetic rats. It reduces the retinal vascular endothelial growth factor (VEGF), TNF-α, ICAM-1, and NO production, and it also has potential to downregulate diabetes-related lipid peroxidation [122]. Eriodictyol treatment may upregulate mRNA expression of PPARγ2 and lipocyte-specific fatty acid-binding protein and the protein level of PPARγ2 in differentiated 3T3-L1 adipocytes. In addition to these effects, eriodictyol also reactivated Akt in HepG2 cells with high glucose- (HG-) induced insulin resistance [123]. Insulin resistance has a close affinity with irregular signaling through IRS-1, P13k, and Akt pathways [124].

3.2. Citrus Flavonoids and DCM. DM is associated with increased risk of developing CVD, the principal cause of death and disability in people with diabetes [6]. DCM describes DM-associated pathological changes in the myocardium, independent of ischemic heart disease or hypertention. The prevalence of DCM has remarkably increased over the past decades [125] and is characterized by diastolic dysfunction, cardiac remodeling, hypertrophy, and altered cardiac energy metabolism [9, 10]. Hyperglycemia-induced excessive production of ROS is the main underlying mechanism of diabetes-induced cardiomyocyte damage [126]. Prolonged hyperglycemia can induce metabolic and molecular changes leading to myocardial injury [127]. Redox imbalance in the diabetic heart leads to oxidative DNA damage and accelerated myocardial apoptosis [128]. Other mechanisms involved in DCM include mitochondrial dysfunction, inflammation, increased AGEs, activation of PKC, and increased flux of hexosamine and polyol pathways [10] (Figure 2). Mitochondrial dysfunction plays a crucial role in the development and progression of DCM [129]. Hyperglycemia impairs the function of mitochondria by altering mitochondrial Ca2+ handling, energy metabolism and oxidative phosphorylation, dynamics, and biogenesis [130]. Hyperglycemia provokes nonenzymatic reaction of glucose with protein amino groups or lipids, leading to increased formation of AGEs [131]. Within the myocardium, AGE accumulation induces structural changes in several proteins, as well as Ca2+ handling, and consequently leads to myocardial stiffness [132]. In addition, AGE accumulation can provoke myocardial fibrosis by increasing collagen cross-linkage, impaired cardiac relaxation, and diastolic dysfunction [133]. Hyperglycemia can also activate the hexosamine synthetic pathway and increase N-acetylglucosamine (GlcNAc), leading to more ROS generation. Increased levels of GlcNAc may induce deactivation of antioxidant defense enzymes via O-GlcNAcylation [134]. Moreover, dyslipidemia, which includes lipoprotein abnormalities, has emerged as a major factor in the pathogenesis of DM-associated CVD [13]. Recently, we reported elevated serum lipids associated with a pronounced increase in cardiovascular risk indices in STZ-induced diabetic rats [135]. Dyslipidemia in diabetic rats has been associated with oxidative stress, inflammation, myocardial fibrosis, and multiple histopathological alterations [135].

Given the role of hyperglycemia, dyslipidemia, and oxidative stress in the pathogenesis of DCM, citrus flavonoids can attenuate myocardial damage in DM via antihyperglycemic, antihyperlipidemic, and antioxidant potential. In this context, several studies have reported the beneficial therapeutic effects of citrus flavonoids in diabetic cardiovascular complications. Hesperidin has been demonstrated to exert a cardioprotective effect in ischemic heart disease in diabetic rats [136]. Hesperidin activated PPARγ signaling and reduced left ventricular end-diastolic pressure and mean arterial pressure in diabetic rats [136]. The efficacy of hesperidin to upregulate PPARγ signaling has been supported by our recent study showing activated hepatic PPARγ following hesperidin supplementation in cyclophosphamide-induced rats [28] and in an experimental model of hepatocarcinogenesis [29]. Hesperetin, the aglycone of hesperidin, has been recently reported to inhibit inflammation and fibrosis in the heart of STZ-induced diabetic rats by suppressing the NF-κB signaling pathway [137]. Treatment of diabetic rats with hesperetin downregulated the expression of proinflammatory cytokines, adhesion molecules, and collagen I and III; inhibited NF-κB activation; and decreased collagen deposition in the heart [137].

Naringin protected cardiomyocytes against hyperglycemia-induced injury both in vitro and in vivo as reported by You et al. [138]. Pretreatment of cardiomyocytes with naringin prevented high glucose-induced oxidative stress, apoptosis, and increased mitochondrial membrane potential (MMP) and NF-κB p65 phosphorylation [138]. These findings were confirmed by in vivo treatment of STZ-induced diabetic rats with naringin. Diabetic rat hearts treated with naringin showed increased expression of ATP-sensitive K+ channels and SOD and decreased the ADP/ATP ratio and NOX4 expression [138]. Recently, Zhang et al. [139] showed the involvement of oxidative stress and ER stress in DCM and the ameliorative role of naringin. STZ-induced diabetic rats treated with naringin for 8 weeks exhibited improved glucose tolerance; enhanced cardiac antioxidants; decreased cardiac lipid peroxidation; downregulated mRNA and
protein expression levels of GRP78, CHOP, and caspase-12; and improved the histological appearance of the myocardium [139]. These findings point to the role of naringin in ameliorating mitochondrial ROS production and inhibiting the ER stress-mediated apoptosis [139]. The aglycone form of naringin, naringenin, showed cardioprotective effects in STZ-diabetic mouse heart. Naringenin ameliorated cardiac hypertrophy in HFD/STZ-diabetic mice through upregulating both the gene and protein expression of PPARs, CYP2J3, and 14,15-EET [140].

In STZ-induced male diabetic mice, nobiletin attenuated oxidative stress, inflammation, and cardiac dysfunction as reported by Zhang et al. [141]. Echocardiography and hemodynamic measurements revealed improved cardiac function in diabetic mice treated with nobiletin. The cardioprotective mechanism of nobiletin included the suppression of NADPH oxidase-mediated ROS production and downregulated the expression of transforming growth factor-β, fibro-nectin, collagen, JNK, P38, and NF-κB. Therefore, nobiletin was able to inhibit NF-κB activation and mitigate fibrosis in the diabetic mouse heart [141].

4. Therapeutic Potential of Citrus Flavonoids in Endothelial Dysfunction (ED) and Atherosclerosis

4.1. Citrus Flavonoids and ED. Endothelial cells produce different and important vasoactive substances for the regulation of the proper vascular function and maintenance of vascular tone in the body. These substances are endothelium-derived hyperpolarizing factor (EDHF), NO, carbon monoxide, prosta-cyclin, endothelin, vasoactive prostanoids, and superoxide [142]. ED is a complex disease, and several factors are responsible for its initiation. ED is characterized by reduced bioavailability of NO because of eNOS uncoupling which might be a consequence of oxidative stress or excess FFA as well as other factors [8, 143–145] (Figure 3). Under oxidative stress conditions, superoxide radical reacts with NO resulting in the formation of ONOO• and decreased NO bioavailability [146]. The generation of free radicals and activated endothelial cells starts the complex pathogenic events [147], which attract the circulating macrophages and internalize modified lipoproteins to become foam cells [148]; multiple cytokines and growth factors detailed by endothelial cells attract the adjacent smooth muscle cells to induce proliferation and production of the extracellular matrix within the inner layer of vessels which ultimately results in generation of fibromuscular plaque [149].

Free radicals and ROS have a significant contribution in the pathogenesis of ED and CVD. The body cells and tissues are in continuous danger from free radicals and ROS which are generated during the normal process of metabolism. Thus, antioxidants can play a central role in boosting the cellular capacity against ROS-induced injury. The antioxidant activity of flavonoids is well-documented, and they protect cells from the lethal free radicals and ROS [150].

Normal arterial pressure is necessary for the healthy activity of the vasculature and normal blood flow. Citrus fruit flavonoids act as vasorelaxants and maintain vasculature tone throughout the body [150]. The vasorelaxant activity of citrus flavonoids also protects arterial intima from ED and from other diseases including metabolic syndrome [151].

A study conducted on spontaneous hypertensive rats (SHR) showed that a continuous 8-week duration of hes-peridin intake can significantly reduce blood pressure, oxidative stress, ED, and cardiac and vascular hypertrophies. Moreover, G-hesperidin (alpha glucosyl hesperidin) intake showed an ability to increase acetylcholine-induced endothelium-dependent vasodilation among SHRs. The same study showed that the intake of G-hesperidin did not affect eNOS gene expression and was not responsible for the increased NO production [152]. In another study, where SHRs were treated with hesperidin, the results
showed a dose-dependent inverse relation with ED and systolic blood pressure [153]. In a diabetic rodent model, the use of hesperidin resulted in hypoglycemia and reduced circulating FFA, triglycerides, and total cholesterol [154]. Human patients diagnosed with hyperlipidemia and treated with G-hesperidin showed lower circulating triglyceride levels [155, 156].

Naringin and naringenin are known as sturdy free radical scavengers and help in the prevention of lipid peroxidation. In an in vitro study, superoxide and hydroxyl radicals were scavenged by these flavonoids [157]. Naringin has the ability to inhibit the activity of XO, an indigenous source of superoxide anions in eukaryotic cells [158]. A study conducted on diabetic rats, where the rats were supplemented with naringin, showed improved and enhanced activity of antioxidant enzymes including SOD, catalase, and GPx [159]. Another study conducted by Jeon et al. [160] on cholesterol-fed rabbits showed that naringin supplementation can increase the activity of antioxidant enzymes; however, the TBARS concentration remained unchanged.

4.2. Citrus Flavonoids and Atherosclerosis. Citrus flavonoids have gained special attention among others, because of their unique and enhanced therapeutic properties against different chronic diseases, particularly atherosclerosis [161, 162]. Flavonoids have very specific antioxidant properties and can protect cells against oxidative damage [162]. A study carried out by Gorinstein et al. showed that the intake of citrus fruit reduces the plasma level of triglycerides in CVD patients [163]. Another recent study on the daily intake of glucosyl hesperidin (500 mg/day for 6 or 24 weeks) showed significantly reduced triglycerides in both hyperlipidemia and hypertriglyceridemia subjects [155, 156]. A study in hypercholesterolemia patients revealed that the intake of naringin (400 mg/day for 8 weeks) can cause 17% reduction in LDL-C and apoB level in plasma [164]. 0.05% naringenin and 0.1% naringin were given to high cholesterol-fed rabbits, and the results showed a reduction in aortic fatty streaks [165].

Different cell model studies were performed for the evaluation of citrus flavonoids. A previous study on HepG2 furnished evidence that both naringenin and hesperetin reduced apoB100 accumulation over the media for four hours [80]. Different studies on HepG2 cells showed that naringenin inhibits cholesterol acyltransferase and microsomal triglyceride transfer proteins which limits cholesteryl ester and triglyceride availability for the formation of lipoprotein [166, 167].

A clinical study of subjects with hypercholesterolemia (cholesterol >230 mg/dl), who received 270 mg of citrus flavonoid and 30 mg of tocotrienols daily for the period of four weeks, revealed significant reductions in total plasma cholesterol (20-30%), LDL (19-27%), and TG (24-34%) [171]. Intake of orange juice (480 ml/day for 1 year) reduced the concentration of total cholesterol, LDL cholesterol, and apoB in patients with mild hypercholesterolemia [172]. Glucosyl hesperidin (500 mg/day for 24 weeks) supplemented to hypertriglyceridemic patients significantly reduced plasma triglyceride and apoB [155]. A larger study conducted on Japanese subjects (10,623 participants: 4,147 male and 6,476 female) using citrus fruit intake (6-7 times/week) demonstrated an inverse association for CVD, specifically ischemic stroke [173].

Rabbits fed cholesterol and a daily intake of 500 mg/kg naringin supplementation showed reduced vascular fatty streak arrangement and macrophage infiltration in vascular walls. In the same study, hypercholesterolemic rabbits treated with naringin showed antiatherogenic activity by inhibiting ICAM-1 expression in endothelial cells [174]. In another study, rabbits with high plasma cholesterol were treated with naringin and naringenin and both showed antiatherogenic effects by downregulating the expression of aortic VCAM-1 and MCP-1 [165]. Increased production of apoB containing lipoproteins is a characteristic feature of dyslipidemia along with insulin resistance [175]. When wild-type mice were supplemented with elevated levels of fat in their diet and naringin, the results showed significant antiatherogenic effects.
Atherosclerosis is a very common disease worldwide, and multiple factors, including hypertension, diabetes, and high plasma cholesterol level, can accelerate its onset. Several medical therapies are available for the treatment of atherosclerosis, but they may have side effects. However, nutritional therapy and balanced diet have gained significant importance in recent years for the treatment of atherosclerosis and other cardiovascular diseases. The use of citrus fruits in daily diet not only provides valuable vitamins and nutrients to the body but also can enhance the metabolism of the body. The flavonoids present in citrus fruits have antioxidant, hypolipidemic, and antiadipic activities and demonstrate a significant role in the control of free radicals. Therefore, citrus flavonoids could be of significant value as a treatment regime for counteracting atherosclerosis. However, clinical studies for the proper evaluation of citrus flavonoids metabolic activity are needed.

5. Citrus Flavonoids and Modulation of Platelet Function

Thrombocytes or platelets play a crucial role in hemostasis and wound healing. However, excessive activation of thrombocytes is associated with many disorders, including DM and hypertension. In addition, platelet dysfunction participates in the pathogenesis and progression of thrombosis and CVD [179]. Flavonoids possess multiple therapeutic benefits against cancer, neurodegenerative disorders, and CVD. Given their antihyperlipidemic effects and their regulatory role in lipid metabolism, flavonoids can reduce cell adhesion and improve the function of vascular endothelium [179–181]. Therefore, flavonoids have been proposed as novel candidates for the development of therapeutic agents counteracting several disease conditions associated with thrombotic events [182, 183].

Epidemiological reports have pointed to the inverse relationship between platelet activity and the consumption of citrus flavonoids. Hence, citrus flavonoids can play a protective role against the pathogenesis and progression of CVD [179, 183–186]. Flavonoids are capable of inhibiting platelet function and hence might be of value as anti-thrombotic agents [183, 186, 187].

The exact mechanisms underlying the antiplatelet activity of citrus flavonoids are not fully elucidated. Studies have demonstrated different mechanisms describing the effect of flavonoids on platelet function. Inhibition of the arachidonic acid-based pathway has been postulated as the primary effect of flavonoids in platelets [179, 180]. Other mechanisms such as mobilization of intracellular Ca^{2+}, attenuation of agonist-induced GPIIb/IIIa receptor activation, and activation of phospholipases and MAPK have been proposed for the reduced platelet activity by flavonoids [182]. However, Ravishankar et al. have recently reported that the underlying mechanism depends specifically on the flavonoid structure and the included functional groups [183]. The antiplatelet activity of citrus flavonoids naringin and naringenin as well as other compounds, such as, coumarin, esculetin, and fraxetin has been tested [186]. Naringin and naringenin showed a more potent ability to bind to and inhibit GPIIb/IIIa receptors which have a role in platelet activation by acting as receptors for fibrinogen and von Willebrand factor [186]. Naringenin improved NTPDase activities in platelets in hypercholesterolemic diet-fed rats [188]. In addition, citrus flavonoids may have an impact on the circulating levels of fibrinogen, factor (F) VII, and plasminogen [184, 187, 189].

The citrus flavonoid tangeretin has also shown antiplatelet activity mediated via inhibition of intracellular calcium mobilization, GPIIb/IIIa receptor signaling, granule secretion, platelet adhesion, and thrombus formation [190]. The impact of tangeretin on platelets has been attributed to inhibition of PI3K signaling and increased cGMP levels in platelets [190].

Nobiletin has also been investigated for its antiplatelet activity. Both in vitro and in vivo experimental studies demonstrated the ability of nobiletin to suppress platelet aggregation, calcium mobilization, granule secretion, and thrombosis. In C57BL/6 mice, nobiletin reduced Akt phosphorylation, increased cGMP, suppressed phospholipase PLCy2 and vasodilator-stimulated phosphoprotein phosphorylation, and extended bleeding time [187]. In addition to the previously mentioned effects, nobiletin suppressed the phosphorylation of Akt, MAPK, and PLCy2 as well as ROS levels in collagen-activated human platelets [185]. Furthermore, incubation of human platelets with nobiletin resulted in increased phosphorylation of vasodilator-stimulated phosphoprotein, a substrate of cAMP and cGMP-regulated protein kinases [191].

6. Concluding Remarks

(i) The available data suggests that citrus flavonoids are likely to confer protection against CVD. The ability of citrus flavonoids to reduce oxidative stress, hyperlipidemia, and inflammation and to improve endothelial function, arterial blood pressure, and lipid metabolism may be responsible for their therapeutic role against atherosclerosis and CVD (Figure 4).

(ii) In vitro and in vivo studies indicate that citrus flavonoids protect against ROS-induced cell injury, reduce obesity and adipose tissue inflammation, and improve platelet function. Citrus flavonoids modulate several signaling pathways controlling inflammation and other processes such as NF-κB

(iii) Studies in experimental diabetes models demonstrate the efficacy of citrus flavonoids to improve glucose tolerance, increase insulin secretion and sensitivity, decrease insulin resistance, reduce hepatic glucose output and intestinal glucose absorption, enhance peripheral glucose uptake,
suppress inflammation, and modulate activity of enzymes and transporters involved in glucose and lipid metabolism.

(iv) Citrus flavonoids modulate different signaling pathways involved in adiposity and adipocyte differentiation and hence could be of significant value for the development of antiobesity agents.

(v) Given the tremendous increase in the number of diabetic patients in the world, there is a greater concern for the development of harmless, efficient, and cost-effective antiobesity medicine. Therefore, further studies and clinical trials to assess the efficacy and to explore the underlying citrus flavonoids mechanism(s) of action are recommended in both healthy subjects and patients. The results of these studies might open new avenues of research in the development of novel therapeutic agents.

Conflicts of Interest

The authors have no conflicts of interest.

References

[1] S. P. Marso, G. H. Daniels, K. Brown-Frandsen et al., “Liraglutide and cardiovascular outcomes in type 2 diabetes,” New England Journal of Medicine, vol. 375, no. 4, pp. 311–322, 2016.

[2] W. Kerner and J. Brückel, “Definition, classification and diagnosis of diabetes mellitus,” Experimental and Clinical Endocrinology & Diabetes, vol. 122, no. 7, pp. 384–386, 2014.

[3] G. C. Davey, S. B. Patil, A. O’Loughlin, and T. O’Brien, “Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus,” Frontiers in Endocrinology, vol. 5, p. 86, 2014.

[4] S. Satta, A. M. Mahmoud, F. L. Wilkinson, M. Yvonne Alexander, and S. J. White, “The role of Nrf2 in cardiovascular function and disease,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 9237263, 18 pages, 2017.

[5] K. Ogurtsova, J. D. da Rocha Fernandes, Y. Huang et al., “IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040,” Diabetes Research and Clinical Practice, vol. 128, pp. 40–50, 2017.

[6] K. Papatheodorou, N. Papanas, M. Banach, D. Papazoglou, and M. Edmonds, “Complications of diabetes 2016,” Journal of Diabetes Research, vol. 2016, Article ID 6989453, 3 pages, 2016.

[7] T. Vanessa Fiorentino, A. Prioulerta, P. Zuo, and F. Foll, “Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases,” Current Pharmaceutical Design, vol. 19, no. 32, pp. 5695–5703, 2013.

[8] R. Jimenez, M. Toral, M. Gómez-Guzmán et al., “The role of Nrf2 signaling in PPARβ/δ-mediated vascular protection against hyperglycemia-induced oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 5852706, 12 pages, 2018.

[9] A. Lorenzo-Almorós, J. Tuñión, M. Orejas, M. Cortés, J. Egido, and O. Lorenzo, “Diagnostic approaches for diabetic cardiomyopathy,” Cardiovascular Diabetology, vol. 16, no. 1, p. 28, 2017.

[10] A. M. Mahmoud, “Exercise ameliorates metabolic disturbances and oxidative stress in diabetic cardiomyopathy: possible underlying mechanisms,” in Exercise for Cardiovascular Disease Prevention and Treatment: From Molecular to Clinical, Part 1, J. Xiao, Ed., pp. 207–230, Springer, Singapore, Singapore, 2017.

[11] V. Lobo, A. Patil, A. Phatak, and N. Chandra, “Free radicals, antioxidants and functional foods: impact on human health,” Pharmacognosy Reviews, vol. 4, no. 8, pp. 118–126, 2010.

[12] G. Filomeni, D. De Zio, and F. Cecconi, “Oxidative stress and autophagy: the clash between damage and metabolic needs,” Cell Death & Differentiation, vol. 22, no. 3, pp. 377–388, 2015.

[13] R. H. Nelson, “Hyperlipidemia as a risk factor for cardiovascular disease,” Preventive Medicine in Office Practice, vol. 40, no. 1, pp. 195–211, 2013.

[14] L. G. Spagnoli, A. Mauriello, G. Sangiorgi et al., “Extracranial thrombetically active carotid plaque as a risk factor for ischemic stroke,” JAMA, vol. 292, no. 15, pp. 1845–1852, 2004.

[15] M. Naghavi, P. Libby, E. Falk et al., “From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I,” Circulation, vol. 108, no. 14, pp. 1664–1672, 2003.

[16] Y. Kitta, J. E. Obata, T. Nakamura et al., “Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease,” Journal of the American College of Cardiology, vol. 53, no. 4, pp. 323–330, 2009.

[17] M. Zabalza, I. Subirana, C. Lluis-Ganella et al., “Association between coronary artery disease genetic variants and subclinical atherosclerosis: an association study and meta-analysis,” Revista Española de Cardiología, vol. 68, no. 10, pp. 869–877, 2015.
[18] M. G. Sorci-Thomas and M. J. Thomas, "High density lipoprotein biogenesis, cholesterol efflux, and immune cell function," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 32, no. 11, pp. 2561–2565, 2012.

[19] H. Bjorkbacka, G. N. Fredrikson, and J. Nilsson, "Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence," *Atherosclerosis*, vol. 227, no. 1, pp. 9–17, 2013.

[20] B. Laflont and K. J. Rayner, "MicroRNAs in the pathobiology and therapy of atherosclerosis," *The Canadian Journal of Cardiology*, vol. 33, no. 3, pp. 313–324, 2017.

[21] O. M. Ahmed, A. M. Mahmoud, A. Abdel-Moneim, and M. B. Ashour, "Antihyperglycemic and antihyperlipidemic effects of hesperidin and naringin in high fat diet/streptozotocin type 2 diabetic rats," *Life Science Journal*, vol. 8, no. 4, pp. 91–101, 2011.

[22] O.M. Ahmed, A.A. Moneim, I.A. Yazid, and A.M. Mahmoud, “Antihyperglycemic, antihyperlipidemic and antioxidant effects and the probable mechanisms of action of Ruta graveolens infusion and rutin in nicotinamide-streptozotocin-induced diabetic rats,” *Diabetologia Croatica*, vol. 39, no. 1, pp. 15–35, 2010.

[23] R. R. Ahmed, A. M. Mahmoud, M. B. Ashour, and A. M. Kamel, "Hesperidin protects against diethylthiolumamine-induced nephrotoxicity through modulation of oxidative stress and inflammation," *National Journal of Physiology, Pharmacy and Pharmacology*, vol. 5, no. 5, pp. 391–397, 2015.

[24] M. S. Aly, S. R. Galaly, N. Moustafa, H. M. Mohammed, S. M. Khadrwaw, and A. M. Mahmoud, "Hesperidin protects against diethylthiolumamine/carbon tetrachloride-induced renal repercussions via up-regulation of Nrf2/HO-1 signaling and attenuation of oxidative stress," *Journal of Applied Pharmacological Science*, vol. 7, no. 11, pp. 7–14, 2017.

[25] E. M. Kamel, A. M. Mahmoud, S. A. Ahmed, and A. M. Lamshabi, "A phytochemical and computational study on flavonoids isolated from *Trifolium resupinatum* L. and their novel hepatoprotective activity," *Food & Function*, vol. 7, no. 4, pp. 2094–2106, 2016.

[26] A. M. Mahmoud, "Influence of rutin on biochemical alterations in hyperammonemia in rats," *Experimental and Toxicologic Pathology*, vol. 64, no. 7–8, pp. 783–789, 2012.

[27] A. M. Mahmoud, "Hematological alterations in diabetic rats - role of adipocytokines and effect of citrus flavonoids," *EXCLI Journal*, vol. 12, pp. 647–657, 2013.

[28] A. M. Mahmoud, "Hesperidin protects against cyclophosphamide-induced hepatotoxicity by upregulation of PPARγ and abrogation of oxidative stress and inflammation," *Canadian Journal of Physiology and Pharmacology*, vol. 92, no. 9, pp. 717–724, 2014.

[29] A. M. Mahmoud, H. M. Mohammed, S. M. Khadrwaw, and S. R. Galaly, "Hesperidin protects against chemically induced hepatocarcinogenesis via modulation of Nrf2/ARE/HO-1, PPARγ and TGF-β1/Smad3 signaling, and amelioration of oxidative stress and inflammation," *Chemico-Biological Interactions*, vol. 277, pp. 146–158, 2017.

[30] E. E. Mulvihill and M. W. Huff, "Antiatherogenic properties of flavonoids: implications for cardiovascular health," *The Canadian Journal of Cardiology*, vol. 26, Supplement A, pp. 17a–21a, 2010.

[31] K. D. Croft, "The chemistry and biological effects of flavonoids and phenolic acids," *Annals of the New York Academy of Sciences*, vol. 854, no. 1 TOWARDS PROLO, pp. 435–442, 1998.

[32] J. Xiao, "Dietary flavonoid glycones and their glycosides: which show better biological significance?" *Critical Reviews in Food Science and Nutrition*, vol. 57, no. 9, pp. 1874–1905, 2017.

[33] R. Xu, Y. Ye, and W. Zhao, *Introduction to Natural Products Chemistry*, Boca Raton: Science Press, 2012.

[34] J. Xiao, E. Capanoglu, A. R. Jassbi, and A. Miron, "Advance on the flavonoid C-glycosides and health benefits," *Critical Reviews in Food Science and Nutrition*, vol. 56, Supplement 1, pp. S29–S45, 2016.

[35] C. Manach, A. Scalbert, C. Morand, C. Rémy, and L. Jiménez, "Polyphenols: food sources and bioavailability," *The American Journal of Clinical Nutrition*, vol. 79, no. 5, pp. 727–747, 2004.

[36] T. Walle, A. M. Browning, L. L. Steed, S. G. Reed, and U. K. Walle, "Flavonoid glycosides are hydrolyzed and thus activated in the oral cavity in humans," *The Journal of Nutrition*, vol. 135, no. 1, pp. 48–52, 2005.

[37] G. Kottra and H. Daniel, "Flavonoid glycosides are not transported by the human Na'/glucose transporter when expressed in *Xenopus laevis* oocytes, but effectively inhibit electrogenic glucose uptake," *The Journal of Pharmacology and Experimental Therapeutics*, vol. 322, no. 2, pp. 829–835, 2007.

[38] Y. Chen, J. Wang, X. Jia, X. Tan, and M. Hu, "Role of intestinal hydrolase in the absorption of prenylated flavonoids present in Yinyanghuo," *Molecules*, vol. 16, no. 2, pp. 1336–1348, 2011.

[39] P. C. H. Hollman and M. B. Katan, "Absorption, metabolism and health effects of dietary flavonoids in man," *Biomedicine & Pharmacotherapy*, vol. 51, no. 8, pp. 305–310, 1997.

[40] C. Manach, C. Morand, O. Texier et al., "Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin," *The Journal of Nutrition*, vol. 125, no. 7, pp. 1911–1922, 1995.

[41] F. L. Courts and G. Williamson, "The C-glycosyl flavonoid, aspalathin, is absorbed, methylated and glucurononated intact in humans," *Molecular Nutrition & Food Research*, vol. 53, no. 9, pp. 1104–1111, 2009.

[42] J. Xiao and P. Hogger, "Metabolism of dietary flavonoids in liver microsomes," *Current Drug Metabolism*, vol. 14, no. 4, pp. 381–391, 2013.

[43] M. D’Archivio, C. Filesi, R. Di Benedetto, R. Gargiulo, C. Giovannini, and R. Masella, "Polyphenols, dietary sources and bioavailability," *Annali dell’Istituto superiore di sanità*, vol. 43, no. 4, pp. 348–361, 2007.

[44] Y. Sun, L. Qiao, Y. Shen, P. Jiang, J. Chen, and X. Ye, "Phytochemical profile and antioxidant activity of physiological drop of citrus fruits," *Journal of Food Science*, vol. 78, no. 1, pp. C37–C42, 2013.

[45] C. Li and H. Schlesener, "Health-promoting effects of the citrus flavanone hesperidin," *Critical Reviews in Food Science and Nutrition*, vol. 57, no. 3, pp. 613–631, 2017.

[46] C. L. Millar, Q. Duclos, and C. N. Blesso, "Effects of dietary flavonoids on reverse cholesterol transport, HDL metabolism, and HDL function," *Advances in Nutrition*, vol. 8, no. 2, pp. 226–239, 2017.

[47] J. Suen, J. Thomas, A. Kranz, S. Vun, and M. Miller, "Effect of flavonoids on oxidative stress and inflammation in adults at..."
risk of cardiovascular disease: a systematic review," *Healthcare*, vol. 4, no. 3, 2016.

[48] N. H. Zaidun, Z. C. Thent, and A. A. Latiff, "Combating oxidative stress disorders with citrus flavonoid: naringenin," *Life Sciences*, vol. 208, pp. 111–122, 2018.

[49] S. M. Abd El-Twab, H. M. Mohamed, and A. M. Mahmoud, "Taurine and pioglitazone attenuate diabetes-induced testicular damage by abrogation of oxidative stress and up-regulation of the pituitary-gonadal axis," *Canadian Journal of Physiology and Pharmacology*, vol. 94, no. 6, pp. 651–661, 2016.

[50] N. M. Al-Rasheed, N. M. Al-Rasheed, I. H. Hasan et al., "Simvastatin ameliorates diabetic cardiomyopathy by attenuating oxidative stress and inflammation in rats," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 1092015, 13 pages, 2017.

[51] A. M. Mahmoud, M. Y. Alexander, Y. Tutar, F. L. Wilkinson, and A. Venditti, "Oxidative stress in metabolic disorders and drug-induced injury: the potential role of Nrf2 and PPARs activators," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 2508909, 4 pages, 2017.

[52] A. M. Al Hroob, M. H. Abukhalil, O. E. Hussein, and A. M. Mahmoud, "Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate," *Biomedicine & Pharmacotherapy*, vol. 109, pp. 2155–2172, 2019.

[53] R. J. Hernandez Bautista, A. M. Mahmoud, M. Konigsberg, and N. E. López Díaz Guerrero, "Obesity: pathophysiology, monosodium glutamate-induced model and anti-obesity medicinal plants," *Biomedicine & Pharmacotherapy*, vol. 111, pp. 503–516, 2019.

[54] E. E. Mulvihill, A. C. Burke, and M. W. Huff, "Citrus flavonoids as regulators of lipoprotein metabolism and atherosclerosis," *Annual Review of Nutrition*, vol. 36, no. 1, pp. 275–299, 2016.

[55] E. Hernandez-Aquino and P. Muriel, "Beneficial effects of naringenin in liver diseases: molecular mechanisms," *World Journal of Gastroenterology*, vol. 24, no. 16, pp. 1679–1707, 2018.

[56] M. Zobeiri, T. Belwal, F. Parvizi et al., "Naringenin and its nano-formulations for fatty liver: cellular modes of action and clinical perspective," *Current Pharmaceutical Biotechnology*, vol. 19, no. 3, pp. 196–205, 2018.

[57] A. N. Panche, A. D. Diwan, and S. R. Chandra, "Flavonoids: an overview," *Journal of Nutraceuticals*, vol. 5, article e47, 2016.

[58] A. M. Mahmoud, M. B. Ashour, A. Abdel-Moneim, and O. M. Ahmed, "Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat/streptozotocin-induced type 2 diabetic rats," *Journal of Diabetes and its Complications*, vol. 26, no. 6, pp. 483–490, 2012.

[59] J. M. Assini, E. E. Mulvihill, and M. W. Huff, "Citrus flavonoids and lipid metabolism," *Current Opinion in Lipidology*, vol. 24, no. 1, pp. 34–40, 2013.

[60] U. J. Jung, M. K. Lee, Y. B. Park, M. A. Kang, and M. S. Choi, "Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice," *The International Journal of Biochemistry & Cell Biology*, vol. 38, no. 7, pp. 1134–1145, 2006.

[61] Z. Úckun, S. Guzel, N. Canancankatan, C. Yalaza, D. Kibar, and B. Coskun Yilmaz, "Potential protective effects of naringenin against vancomycin-induced nephrotoxicity via reduction on apoptotic and oxidative stress markers in rats," *Drug and Chemical Toxicology*, vol. 2018, 8 pages, 2018.

[62] J. Teng, Y. Li, W. Yu et al., "Naringenin, a common flavone, inhibits the formation of AGEs in bread and attenuates AGEs-induced oxidative stress and inflammation in RAW264.7 cells," *Food Chemistry*, vol. 269, pp. 35–42, 2018.

[63] L. Liaquat, Z. Batool, S. Sadir et al., "Naringenin-induced enhanced antioxidant defense system meliorates cholinergic neurotransmission and consolidates memory in male rats," *Life Sciences*, vol. 194, pp. 213–223, 2018.

[64] D. I. Al-Dosari, M. M. Ahmed, S. S. Al-Rejaie, A. S. Alhojima, and M. S. Ola, "Flavonoid naringenin attenuates oxidative stress, apoptosis and improves neurotrophic effects in the diabetic rat retina," *Nutrients*, vol. 9, no. 10, 2017.

[65] K. Wang, Z. Chen, L. Huang et al., "Naringenin reduces oxidative stress and improves mitochondrial dysfunction via activation of the Nrf2/ARE signaling pathway in neurons," *International Journal of Molecular Medicine*, vol. 40, no. 5, pp. 1582–1590, 2017.

[66] S. Cirmi, N. Ferlazzo, G. E. Lombardo et al., "Neurodegenerative diseases: might citrus flavonoids play a protective role?," *Molecules*, vol. 21, no. 10, 2016.

[67] H. Parhiz, A. Roohbakhsh, F. Soltani, R. Rezaee, and M. Iranshahi, "Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models," *Phytotherapy Research*, vol. 29, no. 3, pp. 323–331, 2015.

[68] J. Wang, H. Zhu, Z. Yang, and Z. Liu, "Antioxidative effects of hesperetin against lead acetate-induced oxidative stress in rats," *Indian Journal of Pharmacology*, vol. 45, no. 4, pp. 395–398, 2013.

[69] J. Zhao, Y. Li, J. Gao, and Y. de, "Hesperidin inhibits ovarian cancer cell viability through endoplasmic reticulum stress signaling pathways," *Oncology Letters*, vol. 14, no. 5, pp. 5569–5574, 2017.

[70] C. Wunpathe, P. Potue, P. Maneesai et al., "Hesperidin suppresses renin-angiotensin system mediated NOX2 overexpression and sympathoexcitation in 2K–1C hypertensive rats," *The American Journal of Chinese Medicine*, vol. 46, no. 04, pp. 751–767, 2018.

[71] A. Rezaeyan, G. H. Haddadi, M. Hosseinizadeh, M. Moradi, and M. Najafi, "Radioprotective effects of hesperidin on oxidative damages and histopathological changes induced by X-irradiation in rats heart tissue," *Journal of Medical Physics*, vol. 41, no. 3, pp. 182–191, 2016.

[72] A. Samie, R. Sedaghat, T. Baluchnejadmojarad, and M. Roghani, "Hesperetin, a citrus flavonoid, attenuates testicular damage in diabetic rats via inhibition of oxidative stress, inflammation, and apoptosis," *Life Sciences*, vol. 210, pp. 132–139, 2018.

[73] P. P. Trivedi, S. Kushwaha, D. N. Tripathi, and G. B. Jena, "Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat," *Cardiovascular Toxicology*, vol. 11, no. 3, pp. 215–225, 2011.

[74] M. Wang, D. Meng, P. Zhang et al., "Antioxidant protection of nobiletin, 5-demethylnobiletin, tangeretin, and 5-demethyltangeretin from citrus peel in Saccharomyces cerevisiae," *Journal of Agricultural and Food Chemistry*, vol. 66, no. 12, pp. 3155–3160, 2018.
[75] L. Liu and X. W. Wu, “Nobiletin protects human retinal pigment epithelial cells from hydrogen peroxide-induced oxidative damage,” Journal of Biochemical and Molecular Toxicology, vol. 32, no. 5, article e22052, 2018.

[76] Y. Qu, Y. Liu, L. Chen et al., “Nobiletin prevents cadmium-induced neuronal apoptosis by inhibiting reactive oxygen species and modulating INK/ERK1/2 and Akt/mTOR networks in rats,” Neurological Research, vol. 40, no. 3, pp. 211–220, 2018.

[77] A. M. Mahmoud, R. R. Ahmed, H. A. Soliman, and M. Salah, “Ruta graveolens and its active constituent rutin protect against diethylnitrosamine-induced nephrotoxicity through modulation of oxidative stress,” Journal of Applied Pharmaceutical Science, vol. 5, no. 10, pp. 016–021, 2015.

[78] I. Demonty, Y. Lin, Y. E. M. P. Zebregs et al., “The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women,” The Journal of Nutrition, vol. 140, no. 9, pp. 1615–1620, 2010.

[79] N. M. Borradaile, K. K. Carroll, and E. M. Kurowska, “Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin,” Lipids, vol. 34, no. 6, pp. 591–598, 1999.

[80] L. J. Wilcox, N. M. Borradaile, L. E. de Dreu, and M. W. Huff, “Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP,” Journal of Lipid Research, vol. 42, no. 5, pp. 725–734, 2001.

[81] Y. Lin, M. A. Vermeer, W. Bos et al., “Molecular structures of citrus flavonoids determine their effects on lipid metabolism in HepG2 cells by primarily suppressing apoB secretion,” Journal of Agricultural and Food Chemistry, vol. 59, no. 9, pp. 4496–4503, 2011.

[82] B. Morin, L. A. Nichols, K. M. Zalasky, J. W. Davis, J. A. Manthey, and L. J. Holland, “The citrus flavonoids hesperetin and nobiletin differentially regulate low density lipoprotein receptor gene transcription in HepG2 liver cells,” The Journal of Nutrition, vol. 138, no. 7, pp. 1274–1281, 2008.

[83] N. A. Bawazeer, H. Choudhry, M. A. Zamzami, W. H. Abdualla, B. Middleton, and S. S. Moselhy, “Role of hesperetin in LDL-receptor expression in hepatoma HepG2 cells,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, p. 182, 2016.

[84] N. A. Bawazeer, H. Choudary, M. A. Zamzami et al., “Possible regulation of LDL-receptor by naringenin in Hepg2 hepatoma cell line,” African Journal of Traditional, Complementary, and Alternative Medicines, vol. 14, no. 1, pp. 278–287, 2017.

[85] H. Suzuki, A. Asakawa, N. Kawamura, T. Yagi, and A. Imai, “Hesperidin potentiates ghrelin signaling,” Recent Patents on Food, Nutrition & Agriculture, vol. 6, no. 1, pp. 60–63, 2014.

[86] H. Peng, Z. Wei, H. Luo et al., “Inhibition of fat accumulation by hesperidin in Caenorhabditis elegans,” Journal of Agricultural and Food Chemistry, vol. 64, no. 25, pp. 5207–5214, 2016.

[87] A. Leyva-Soto, L. R. Lara-Jacobó, L. N. González-Cobian, and R. A. Chavez-Santoscoy, “Daily consumption of a chocolate rich in flavonoids decreases cellular genotoxicity and improves biochemical parameters of lipid and glucose metabolism,” Molecules, vol. 23, no. 9, 2018.

[88] F. Hadrich and S. Sayadi, “Apigetrin inhibits adipogenesis in 3T3-L1 cells by downregulating PPARγ and CEBP-α,” Lipids in Health and Disease, vol. 17, no. 1, p. 95, 2018.

[89] J. Lone, H. A. Parray, and J. W. Yun, “Nobiletin induces brown adipocyte-like phenotype and ameliorates stress in 3T3-L1 adipocytes,” Biochimie, vol. 146, pp. 97–104, 2018.

[90] P. L. Yang, J. P. Jiang, Q. Q. Li, X. M. Wu, and Z. Y. Chen, “Effects of pure total flavonoids from Citrus changshanyou on blood lipid metabolism in hyperlipidemic rats,” China Journal of Chinese Materia Medica, vol. 42, no. 5, pp. 936–943, 2017.

[91] R. Hernández-Bautista, F. Alarcón-Aguilar, M. D. C. Escobar-Villanueva et al., “Biochemical alterations during the obese-aging process in female and male monosodiumglutamate (MSG)-treated mice,” International Journal of Molecular Sciences, vol. 15, no. 7, pp. 11473–11494, 2014.

[92] A. C. Burke, B. G. Sutherland, D. E. Telford et al., “Intervention with citrus flavonoids reverses obesity and improves metabolic syndrome and atherosclerosis in obese Ldlr/−/− mice,” Journal of Lipid Research, vol. 59, no. 9, pp. 1714–1728, 2018.

[93] R. C. L. A. Coelho, H. H. M. Hermsdorff, and J. Bressan, “Anti-inflammatory properties of orange juice: possible favorable molecular and metabolic effects,” Plant Foods for Human Nutrition, vol. 68, no. 1, pp. 1–10, 2013.

[94] A. M. Mahmoud, S. M. Abd El-Twab, and E. S. Abdel-Reheim, “Consumption of polyphenol-rich Morus alba leaves extract attenuates early diabetic retinopathy: the underlying mechanism,” European Journal of Nutrition, vol. 56, no. 4, pp. 1671–1684, 2017.

[95] N. Maulik, Cardiovascular Diseases: Nutritional and Therapeutic Interventions, FL: CRC Press, Boca Raton, 2013.

[96] X. Liu, N. Wang, S. Fan et al., “The citrus flavonoid naringenin confers protection in a murine endotoxaemia model through AMPK-ATF3-dependent negative regulation of the TLR4 signalling pathway,” Scientific Reports, vol. 6, no. 1, article 39735, 2016.

[97] H. P. Kim, K. H. Son, H. W. Chang, and S. S. Kang, “Anti-inflammatory plant flavonoids and cellular action mechanisms,” Journal of Pharmacological Sciences, vol. 96, no. 3, pp. 229–245, 2004.

[98] C. Spagnuolo, S. Moccia, and G. L. Russo, “Anti-inflammatory effects of flavonoids in neurodegenerative disorders,” European Journal of Medicinal Chemistry, vol. 153, pp. 105–115, 2018.

[99] J. Y. Ke, T. Banh, Y. H. Hsiao et al., “Citrus flavonoid naringenin reduces mammary tumor cell viability, adipose mass, and adipose inflammation in obese ovariectomized mice,” Molecular Nutrition & Food Research, vol. 61, no. 9, 2017.

[100] J. Y. Ke, K. L. Kliever, E. M. Hamad et al., “The flavonoid, naringenin, decreases adipose tissue mass and attenuates ovariectomy-associated metabolic disturbances in mice,” Nutrition & Metabolism, vol. 12, no. 1, p. 1, 2015.

[101] H. Yoshida, N. Takamura, T. Shuto et al., “The citrus flavonoids hesperetin and naringenin block the lipolytic actions of TNF-α in mouse adipocytes,” Biochemical and Biophysical Research Communications, vol. 394, no. 3, pp. 728–732, 2010.

[102] H. Yoshida, W. Watanabe, H. Oomagari, E. Tsuruta, M. Shida, and M. Kurokawa, “Citrus flavonoid naringenin inhibits TLR2 expression in adipocytes,” The Journal of Nutritional Biochemistry, vol. 24, no. 7, pp. 1276–1284, 2013.

[103] H. Yoshida, H. Watanabe, A. Ishida et al., “Naringenin suppresses macrophage infiltration into adipose tissue in an early
phase of high-fat diet-induced obesity,” Biochemical and Biophysical Research Communications, vol. 454, no. 1, pp. 95–101, 2014.

[104] N. H. Cho, J. E. Shaw, S. Karuranga et al., “IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045,” Diabetes Research and Clinical Practice, vol. 138, pp. 271–281, 2018.

[105] A. K. Imakume and M. C. Gulliford, “Trends in type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991-2008,” Diabetic Medicine, vol. 28, no. 7, pp. 811–814, 2011.

[106] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, Supplement 1, pp. S62–S69, 2010.

[107] A. B. Olokoba, O. A. Obateru, and L. B. Olokoba, “Type 2 diabetes mellitus: a review of current trends,” Oman Medical Journal, vol. 27, no. 4, pp. 269–273, 2012.

[108] R. A. DeFronzo, “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus,” Diabetes, vol. 58, no. 4, pp. 773–795, 2009.

[109] American Diabetes Association, “Standards of Medical Care in Diabetes—2015 abridged for primary care providers,” Clinical Diabetes, vol. 33, no. 2, pp. 97–111, 2015.

[110] P. Rajendran, N. Nandakumar, T. Rengarajan et al., “Antioxidants and human diseases,” Clinica Chimica Acta, vol. 436, pp. 332–347, 2014.

[111] A. Rodriguez-Casado, “The health potential of fruits and vegetables phytochemicals: notable examples,” Critical Reviews in Food Science and Nutrition, vol. 56, no. 7, pp. 1097–1107, 2016.

[112] P. S. M. Prince and N. Kamalakkannan, “Rutin improves glucose homeostasis in streptozotocin diabetic mice by altering glycolytic and gluconeogenic enzymes,” Journal of Biochemical and Molecular Toxicology, vol. 20, no. 2, pp. 96–102, 2006.

[113] K. Sattanathan, C. K. Dhanapal, R. Umarani, and R. Manavalan, “Beneficial health effects of rutin supplementation in patients with diabetes mellitus,” Journal of Applied Pharmaceutical Science, vol. 1, no. 8, pp. 227–231, 2011.

[114] J. F. C. Guimaraes, B. P. Muzio, C. M. Rosa et al., “Rutin administration attenuates myocardial dysfunction in diabetic rats,” Cardiovascular Diabetology, vol. 14, no. 1, p. 90, 2015.

[115] Q. Liu, S. Wang, and L. Cai, “Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage,” Journal of Diabetes Investigation, vol. 5, no. 6, pp. 623–634, 2014.

[116] K. Kanda, K. Nishi, A. Kadota, S. Nishimoto, M. C. Liu, and T. Sugahara, “Nobiletin suppresses adipocyte differentiation of 3T3-L1 cells by an insulin and IBMX mixture induction,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1820, no. 4, pp. 461–468, 2012.

[117] Y. S. Lee, B. Y. Cha, K. Saito et al., “Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice,” Biochemical Pharmacology, vol. 79, no. 11, pp. 1674–1683, 2010.

[118] L. Pari and S. Srinivasan, “Antihyperglycemic effect of dionisin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats,” Biomedicine & Pharmacotherapy, vol. 64, no. 7, pp. 477–481, 2010.

[119] E. Tripoli, M. L. Guardia, S. Giammanco, D. D. Majo, and M. Giammanco, “Citrus flavonoids: molecular structure, biological activity and nutritional properties: a review,” Food Chemistry, vol. 104, no. 2, pp. 466–479, 2007.

[120] A. Visnagri, A. D. Kandhare, S. Chakravarty, P. Ghosh, and S. L. Bodhankar, “Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions,” Pharmaceutical Biology, vol. 52, no. 7, pp. 814–828, 2014.

[121] A. M. Mahmoud, O. M. Ahmed, M. B. Ashour, and A. Abdel-Moneim, “In vivo and in vitro antidiabetic effects of citrus flavonoids; a study on the mechanism of action,” International Journal of Diabetes in Developing Countries, vol. 35, no. 3, pp. 250–263, 2015.

[122] C. Buco, G. M. Leggio, F. Drago, and S. Salomone, “Eriodictyol prevents early retinal and plasma abnormalities in streptozotocin-induced diabetic rats,” Biochemical Pharmacology, vol. 84, no. 1, pp. 88–92, 2012.

[123] W. Y. Zhang, J. J. Lee, Y. Kim et al., “Effect of eriodictyol on glucose uptake and insulin resistance in vitro,” Journal of Agricultural and Food Chemistry, vol. 60, no. 31, pp. 7652–7658, 2012.

[124] B. Desvergne and W. Wahli, “ Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.

[125] T. Miki, S. Yuda, H. Kouzu, and T. Miura, “Diabetic cardiomyopathy: pathophysiology and clinical features,” Heart Failure Reviews, vol. 18, no. 2, pp. 149–166, 2013.

[126] B. M. Leon and T. M. Maddox, “Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research,” World Journal of Diabetes, vol. 6, no. 13, article 1246, 1258 pages, 2015.

[127] C. Barman, R. Pandey, J. Singh, and et al.K. Sudhi, International Journal of Research in Medical Sciences, vol. 3, no. 7, pp. 1564–1570, 2015.

[128] M. M. Dallak, D. P. Mikhalidis, M. A. Haidara et al., “Oxidative stress as a common mediator for apoptosis induced-cardiac damage in diabetic rats,” The Open Cardiovascular Medicine Journal, vol. 2, no. 1, pp. 70–78, 2008.

[129] J. G. Duncan, “Mitochondrial dysfunction in diabetic cardiomyopathy,” Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1813, no. 7, pp. 1351–1359, 2011.

[130] H. Bugger and E. D. Abel, “Mitochondria in the diabetic heart,” Cardiovascular Research, vol. 88, no. 2, pp. 229–240, 2010.

[131] S. Bansal, D. Chawla, M. Siddarth, B. D. Banerjee, S. V. Madhu, and A. K. Tripathi, “A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications,” Clinical Biochemistry, vol. 46, no. 6, pp. 109–114, 2013.

[132] S. Yamagishi, N. Nakamura, M. Suematsu, K. Kaseda, and T. Matsui, “Advanced glycation end products: a molecular target for vascular complications in diabetes,” Molecular Medicine, vol. 21, Supplement 1, pp. 1–S40, 2015.

[133] H. Bugger and E. D. Abel, “Molecular mechanisms of diabetic cardiomyopathy,” Diabetologia, vol. 57, no. 4, pp. 660–671, 2014.

[134] U. Rajamani and M. F. Essop, “Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis,” American Journal of Physiology-Cell Physiology, vol. 299, no. 1, pp. C139–C147, 2010.

[135] N. M. Al-Rasheed, N. M. Al-Rasheed, I. H. Hasan, M. A. Al-Amin, H. N. Al-Ajmi, and A. M. Mahmoud, “Sitagliptin
attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats,” *Drug Design, Development and Therapy*, vol. 10, pp. 2095–2107, 2016.

[136] Y. O. Agrawal, P. K. Sharma, B. Shrivastava et al., “Hesperidin produces cardioprotective activity via PPAR-y pathway in ischemic heart disease model in diabetic rats,” *PLoS ONE*, vol. 9, no. 11, article e111212, 2014.

[137] Y. Yin, Y. Xu, H. Ma, and X. Tian, “Hesperetin ameliorates cardiac inflammation and cardiac fibrosis in streptozotocin-induced diabetic rats by inhibiting NF-kB signaling pathway,” *Biomedical Research*, vol. 28, no. 1, pp. 223–229, 2017.

[138] Q. You, Z. Wu, B. Wu et al., “Naringin protects cardiomyocytes against hyperglycemia-induced injuries in vitro and in vivo,” *The Journal of Endocrinology*, vol. 230, no. 2, pp. 197–214, 2016.

[139] N. F. Zhang, N. N. Meng, H. Z. Li et al., “Effect of naringin on oxidative stress and endoplasmic reticulum stress in diabetic cardiomyopathy,” *China Journal of Chinese Materia Medica*, vol. 43, no. 3, pp. 596–602, 2018.

[140] J. Zhang, H. Qiu, J. Huang et al., “Naringenin exhibits the protective effect on cardiac hypertrophy via EETs-PPARs activation in streptozotocin-induced diabetic mice,” *Biochemical and Biophysical Research Communications*, vol. 502, no. 1, pp. 55–61, 2018.

[141] N. Zhang, Z. Yang, S. Z. Xiang et al., “Nobiletin attenuates cardiac dysfunction, oxidative stress, and inflammatory in streptozotocin: induced diabetic cardiomyopathy,” *Molecular and Cellular Biochemistry*, vol. 417, no. 1-2, pp. 87–96, 2016.

[142] M. A. Gimbrone Jr., “Vascular endothelium: nature’s blood-compatible container,” *Annals of the New York Academy of Sciences*, vol. 516, pp. 5–11, 1987.

[143] A. M. Mahmoud, F. L. Wilkinson, A. M. Jones et al., “A novel role for small molecule glycometics in the protection against lipid-induced endothelial dysfunction: involvement of Akt/eNOS and Nrf2/ARE signaling,” *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1861, no. 1, pp. 3311–3322, 2017.

[144] A. M. Mahmoud, F. L. Wilkinson, E. M. McCarthy et al., “Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress,” *The FASEB Journal*, vol. 31, no. 10, pp. 4636–4648, 2017.

[145] M. Toral, M. Romero, R. Jiménez et al., “Carnitine palmitoyltransferase-1 up-regulation by PPAR-β/δ prevents lipid-induced endothelial dysfunction,” *Clinical Science*, vol. 129, no. 9, pp. 823–837, 2015.

[146] M. A. Gimbrone Jr. and G. Garcia-Cardenas, “Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis,” *Cardiovascular Pathology*, vol. 22, no. 1, pp. 9–15, 2013.

[147] R. Virmani, F. D. Kolodgie, A. P. Burke, A. Farb, and S. M. Schwartz, “Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 5, pp. 1262–1275, 2000.

[148] N. Simionescu, E. Vasile, F. Lupu, G. Popescu, and M. Simionescu, “Preliminary events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit,” *The American Journal of Pathology*, vol. 123, no. 1, pp. 109–125, 1986.

[149] R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” *Nature*, vol. 362, no. 6423, pp. 801–809, 1993.

[150] B. Fuhrman and M. Aviram, “Flavonoids protect LDL from oxidation and attenuate atherosclerosis,” *Current Opinion in Lipidology*, vol. 12, no. 1, pp. 41–48, 2001.

[151] S. Rizza, R. Muniyappa, M. Iantorno et al., “Citrus polyphenol nesoterol stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 96, no. 5, pp. E782–E792, 2011.

[152] M. Yamamoto, A. Suzuki, H. Jokura, N. Yamamoto, and T. Hase, “Glucosyl hesperidin prevents endothelial dysfunction and oxidative stress in spontaneously hypertensive rats,” *Nutrition*, vol. 24, no. 5, pp. 470–476, 2008.

[153] M. Yamamoto, A. Suzuki, and T. Hase, “Short-term effects of glucosyl hesperidin and hesperetin on blood pressure and vascular endothelial function in spontaneously hypertensive rats,” *Journal of Nutritional Science and Vitaminology*, vol. 54, no. 1, pp. 95–98, 2008.

[154] S. Akiyama, S. Tomasawa, K. Suzuki, Y. Ishimi, J. Wu, and M. Uchiara, “Dietary hesperidin exerts hypoglyemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats,” *Journal of Clinical Biochemistry and Nutrition*, vol. 46, no. 1, pp. 87–92, 2010.

[155] Y. Miwa, H. Mitsuzumi, T. Sunayama et al., “Glucosyl hesperidin lowers serum triglyceride level in hyperglycemic-demenestic subjects through the improvement of very low-density lipoprotein metabolic abnormality,” *Journal of Nutritional Science and Vitaminology*, vol. 51, no. 6, pp. 460–470, 2005.

[156] Y. Miwa, M. Yamada, T. Sunayama et al., “Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level,” *Journal of Nutritional Science and Vitaminology*, vol. 50, no. 3, pp. 211–218, 2004.

[157] M. Cavia-Saiz, M. D. Busto, M. C. Pilar-Izquierdo, N. Ortega, M. Perez-Mateos, and P. Muniz, “The effects of glucosyl hesperidin and probucol in cholesterol-fed rabbits,” *Journal of the Science of Food and Agriculture*, vol. 90, no. 7, pp. 1238–1244, 2010.

[158] A. Russo, R. Acquaviva, A. Campisi et al., “Bioflavonoids as antiradicals, antioxidants and DNA cleavage protectors,” *Cell Biology and Toxicology*, vol. 16, no. 2, pp. 91–98, 2000.

[159] V. R. Punithavathi, R. Anuthama, and P. S. M. Prince, “Combined treatment with naringin and vitamin C ameliorates streptozotocin-induced diabetes in male Wistar rats,” *Journal of Applied Toxicology*, vol. 28, no. 6, pp. 806–813, 2008.

[160] S. M. Jeon, S. H. Bok, M. K. Jang et al., “Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits,” *Clinica Chimica Acta*, vol. 317, no. 1-2, pp. 181–190, 2002.

[161] H. Chen, M. S. Ward, Y. Wu et al., “Dietary patterns and adenocarcinoma of the esophagus and distal stomach,” *The American Journal of Clinical Nutrition*, vol. 75, no. 1, pp. 137–144, 2002.

[162] R. R. Huxley and H. A. W. Neil, “The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies,” *European Journal of Clinical Nutrition*, vol. 57, no. 8, pp. 904–908, 2003.
[163] S. Gorinstein, A. Caspi, I. Libman et al., “Red grapefruit positively influences serum triglyceride level in patients suffering from coronary atherosclerosis: studies in vitro and in humans,” Journal of Agricultural and Food Chemistry, vol. 54, no. 5, pp. 1887–1892, 2006.

[164] U. J. Jung, H. J. Kim, J. S. Lee et al., “Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects,” Clinical Nutrition, vol. 22, no. 6, pp. 561–568, 2003.

[165] C. H. Lee, T. S. Jeong, Y. K. Choi et al., “Anti-atherogenic effect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits,” Biochemical and Biophysical Research Communications, vol. 284, no. 3, pp. 681–688, 2001.

[166] N. M. Borradaile, L. E. de Dreu, P. H. R. Barrett, C. D. Behrsin, and M. W. Huff, “Hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal triglyceride accumulation,” Biochemistry, vol. 42, no. 5, pp. 1283–1291, 2003.

[167] N. M. Borradaile, L. E. de Dreu, P. H. R. Barrett, and M. W. Huff, “Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters,” Journal of Lipid Research, vol. 43, no. 9, pp. 1544–1554, 2002.

[168] Y. Fukuchi, M. Hiramitsu, M. Okada et al., “Lemon polyphenols suppress diet-induced obesity by up-regulation of mRNA levels of the enzymes involved in β-oxidation in mouse white adipose tissue,” Journal of Clinical Biochemistry and Nutrition, vol. 43, no. 3, pp. 201–209, 2008.

[169] H. J. Park, U. J. Jung, S. J. Cho, H. K. Jung, S. Shim, and M. S. Choi, “Citrus unshiu peel extract ameliorates hyperglycemia and hepatic steatosis by altering inflammation and hepatic glucose- and lipid-regulating enzymes in db/db mice,” The Journal of Nutritional Biochemistry, vol. 24, no. 2, pp. 419–427, 2013.

[170] Y. Chtourou, H. Fetoui, R. Jemai, A. Ben Slama, M. Makni, and R. Gdoura, “Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor κB pathway,” European Journal of Pharmacology, vol. 746, pp. 96–105, 2015.

[171] J. M. Roza, Z. Xian-Liu, and N. Guthrie, “Effect of citrus flavonoids and tocochromanols on serum cholesterol levels in hypercholesterolemic subjects,” Alternative Therapies in Health and Medicine, vol. 13, no. 6, pp. 44–48, 2007.

[172] N. P. Aptekmann and T. B. Cesar, “Long-term orange juice consumption is associated with low LDL-cholesterol and apolipoprotein B in normal and moderately hypercholesterolemic subjects,” Lipids in Health and Disease, vol. 12, no. 1, p. 119, 2013.

[173] T. Yamada, S. Hayasaka, Y. Shibata et al., “Frequency of citrus fruit intake is associated with the incidence of cardiovascular disease: the Jichi Medical School cohort study,” Journal of Epidemiology, vol. 21, no. 3, pp. 169–175, 2011.

[174] S. C. Choi, H. S. Kim, T. S. Jeong, S. H. Bok, and Y. R. Park, “Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits,” Journal of Cardiovascular Pharmacology, vol. 38, no. 6, pp. 947–955, 2001.

[175] S. Merat, F. Casanada, M. Surp, W. Palinski, and P. D. Reaven, “Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 5, pp. 1223–1230, 1999.

[176] A. Chanet, D. Milenkovic, C. Deval et al., “Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice,” The Journal of Nutritional Biochemistry, vol. 23, no. 5, pp. 469–477, 2012.

[177] E. M. Allister, E. E. Mulvihill, P. H. R. Barrett, J. Y. Edwards, L. P. Carter, and M. W. Huff, “Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor,” Journal of Lipid Research, vol. 49, no. 10, pp. 2218–2229, 2008.

[178] E. E. Mulvihill, J. M. Assini, B. G. Sutherland et al., “Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 4, pp. 742–748, 2010.

[179] C. Faggio, A. Sureda, S. Morabito et al., “Flavonoids and platelet aggregation: a brief review,” European Journal of Pharmacology, vol. 807, pp. 91–101, 2017.

[180] J. Karlicková, M. Říha, T. Filipík, K. Macáková, R. Hrdina, and P. Mladěnka, “Antiplatelet effects of flavonoids mediated by inhibition of arachidonic acid based pathway,” Planta Medica, vol. 82, no. 1–2, pp. 76–83, 2016.

[181] A. D. Assefa, E. Y. Ko, S. H. Moon, and Y. S. Keum, “Antioxidant and antiplatelet activities of flavonoid-rich fractions of three citrus fruits from Korea,” 3 Biotech, vol. 6, no. 1, p. 109, 2016.

[182] J. J. Lopez, M. El Haouari, I. Jardin et al., “Flavonoids and platelet-derived thrombotic disorders,” Current Medicinal Chemistry, 2018.

[183] D. Ravishankar, M. Salamah, A. Akimbaev et al., “Impact of specific functional groups in flavonoids on the modulation of platelet activation,” Scientific Reports, vol. 8, no. 1, article 9528, 2018.

[184] R. Bucki, J. J. Pastore, F. Giraud, J. C. Sulpice, and P. A. Janmey, “Flavonoid inhibition of platelet procoagulant activity and phosphoinositide synthesis,” Journal of Thrombosis and Haemostasis, vol. 1, no. 8, pp. 1820–1828, 2003.

[185] W. J. Lu, K. C. Lin, C. P. Liu et al., “Prevention of arterial thrombosis by nobiletin: in vitro and in vivo studies,” The Journal of Nutritional Biochemistry, vol. 28, pp. 1–8, 2016.

[186] C. Zaragozá, J. Monserrat, C. Mantecon, L. Vilaescusa, F. Zaragozá, and M. Alvarez-Mon, “Antiplatelet activity of flavonoid and coumarin drugs,” Vascular Pharmacology, vol. 87, pp. 139–149, 2016.

[187] S. Vaiyapuri, H. Roweth, M. S. Ali et al., “Pharmacological actions of nobiletin in the modulation of platelet function,” British Journal of Pharmacology, vol. 172, no. 16, pp. 4133–4145, 2015.

[188] Y. Chtourou, Z. Kamoun, W. Zarrouk et al., “Naringenin ameliorates renal and platelet purinergic signalling alterations in high-cholesterol fed rats through the suppression of ROS and NF-kB signaling pathways,” Food & Function, vol. 7, no. 1, pp. 183–193, 2016.

[189] J. A. Guererro, M. L. Lozano, J. Castillo, O. Benavente-Garcia, V. Vicente, and J. Rivera, “Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor,” Oxidative Medicine and Cellular Longevity
[190] S. Vaiyapuri, M. S. Ali, L. A. Moraes et al., "Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 12, pp. 2740–2749, 2013.

[191] T. Jayakumar, K. C. Lin, W. J. Lu et al., "Nobiletin, a citrus flavonoid, activates vasodilator-stimulated phosphoprotein in human platelets through non-cyclic nucleotide-related mechanisms," *International Journal of Molecular Medicine*, vol. 39, no. 1, pp. 174–182, 2017.